A novel anti-seminoma monoclonal antibody (M2A) labelled with technetium-99m: potential application for radioimmunoscintigraphy. 1995

A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.

OBJECTIVE To study the potential usefulness of monoclonal antibody (mAb) M2A specific for seminoma to image tumour nodules in a preclinical nude mouse model. METHODS MAb M2A was labelled with technetium-99m (99mTc) following reduction and was administered intraperitoneally to nude mice bearing subcutaneous HEY cell xenografts against which the antibody was originally raised. Biodistribution and gamma scintigraphy studies were performed 24 h after administration of 99mTc-M2A. RESULTS Biodistribution studies showed specific targeting of 99mTc-M2A to HEY tumours in comparison with control mAb 99mTc-6E8 and 99mTc-2G3 which do not bind to HEY cells. Subcutaneous HEY cell tumours (0.5-1.0 g) were successfully imaged using gamma-scintigraphy following administration of 99mTc-M2A. CONCLUSIONS The results of this study indicate the potential usefulness of 99mTc-M2A as a clinical reagent for imaging seminoma metastases.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D013370 Subrenal Capsule Assay In vivo method of screening investigative anticancer drugs and biologic response modifiers for individual cancer patients. Fresh tumor tissue is implanted under the kidney capsule of immunocompetent mice or rats; gross and histological assessments follow several days after tumor treatment in situ. Subrenal Capsule Xenograft Assay,Assay, Subrenal Capsule,Assays, Subrenal Capsule,Subrenal Capsule Assays
D013667 Technetium The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m Technetium 99m,99m, Technetium
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D016719 Radioimmunodetection Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera. Immunoscintigraphy, Radiolabeled,Radioimmunoimaging,Radioimmunoscintigraphy,Immunoscintigraphy, Radiolabelled,Radiolabeled Immunoscintigraphy,Radiolabelled Immunoscintigraphy,Immunoscintigraphies, Radiolabeled,Immunoscintigraphies, Radiolabelled,Radioimmunodetections,Radioimmunoimagings,Radioimmunoscintigraphies,Radiolabeled Immunoscintigraphies,Radiolabelled Immunoscintigraphies

Related Publications

A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
August 1993, European journal of nuclear medicine,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
November 1993, European journal of nuclear medicine,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
June 1993, European journal of nuclear medicine,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
July 1995, European journal of nuclear medicine,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
June 1996, European journal of nuclear medicine,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
March 1996, British journal of urology,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
April 1997, European journal of nuclear medicine,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
February 1994, Annals of nuclear medicine,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
September 1993, Nuclear medicine communications,
A Marks, and J R Ballinger, and R M Reilly, and J Law, and R Baumal
December 1995, Cancer research,
Copied contents to your clipboard!